Work

Abstract CT187: Phase 1 Trial of RTX-240, allogeneic red blood cells engineered to express 4-1BBL and trans-presented IL-15, in patients (Pts) with advanced solid tumors

Year: 2022

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2022-ct187

Authors: Omid Hamid, Melissa L. Johnson, Jason Luke, Richard T. Maziarz, Jamie Merchan, Emerson E. Lim, Sandip P. Patel, Geoffrey M. Kuesters, Iga Sienczylo, Gilad Gordon, Karen Campbell, Kristin Horton, Laurence Turka, Alexander I. Spira

Institutions: Angeles Clinic and Research Institute, Tennessee Oncology, University of Pittsburgh, Oregon Health & Science University, University of Miami, Sylvester Comprehensive Cancer Center, Columbia University Irving Medical Center, University of California San Diego, Moores Cancer Center, Rubius Therapeutics (United States), Johns Hopkins Medicine

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4282972582

Cites:

Cited by: 3

Related to: 10